Wide Ranks

KOD

Kodiak Sciences Inc

6.55

Top Statistics
Market Cap 344 M Forward PE -1.76 Revenue Growth 0.00 %
Current Ratio 10.59 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.6990 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 219 M Total Cash Per Share 4.18 Total Debt 75 M
Total Debt To Equity 35.32 Current Ratio 10.59 Book Value Per Share 5.08
All Measures
Short Ratio 519.00 % Message Board Id finmb_321992085 Shares Short Prior Month 1 M
Return On Equity -0.7149 City Palo Alto Uuid 557800df-7007-3d0a-a42a-afe9fdcb28bd
Previous Close 6.56 First Trade Date Epoch Utc 1 B Book Value 5.08
Beta 2.25 Total Debt 75 M Volume 387767
Price To Book 1.29 Fifty Two Week Low 2.19 Total Cash Per Share 4.18
Shares Short Previous Month Date 1 B Target Median Price 4.50 Audit Risk 8
Max Age 86400 Recommendation Mean 3.12 Sand P52 Week Change 0.3133
Target Mean Price 4.33 Net Income To Common -197679008 Short Percent Of Float 0.0401
Implied Shares Outstanding 52 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 423520 Average Volume10days 423520 Total Cash 219 M
Next Fiscal Year End 1 B Held Percent Insiders 0.0566 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 8
Regular Market Previous Close 6.56 Target Low Price 2.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 3.92 Open 6.63 Free Cashflow -111899128
State CA Dividend Yield 0.00 % Return On Assets -0.2672
Time Zone Short Name EST Board Risk 9 Trailing Eps -3.64
Day Low 6.43 Address1 1200 Page Mill Road Shares Outstanding 52 M
Compensation Risk 10 Price Hint 2 Target High Price 6.00
Website https://kodiak.com 52 Week Change 1.71 Average Volume 274442
Forward Eps -3.80 Recommendation Key hold Compensation As Of Epoch Date 1 B
Quick Ratio 1033.90 % Is_sp_500 False Regular Market Day High 6.95
Profit Margins 0.00 % Debt To Equity 35.32 Fifty Two Week High 7.77
Day High 6.95 Shares Short 1 M Regular Market Open 6.63
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0247 Operating Cashflow -131096000 Currency USD
Time Zone Full Name America/New_York Market Cap 344 M Is_nasdaq_100 False
Zip 94304 Quote Type EQUITY Industry Biotechnology
Long Name Kodiak Sciences Inc. Overall Risk 10 Regular Market Day Low 6.43
Held Percent Institutions 0.7779 Current Price 6.55 Enterprise To Ebitda -0.6990
Financial Currency USD Current Ratio 10.59 Industry Disp Biotechnology
Number Of Analyst Opinions 6 Country United States Float Shares 32 M
Two Hundred Day Average 3.70 Governance Epoch Date 1 B Enterprise Value 134 M
Forward PE -1.76 Regular Market Volume 387767 Ebitda -192783008
Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.

Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.

The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions.

The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015.

Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.